AICAR — 5-aminoimidazole-4-carboxamide ribonucleotide, also studied as the drug acadesine — is best known from a single headline: the 2008 mouse study that dubbed it "exercise in a pill." Inside the cell it is phosphorylated to ZMP, a molecule that mimics AMP and switches on AMPK, the master low-energy sensor that exercise also activates. That mechanism is real and well-documented.
The gap that matters is between the mechanism and the marketing. Activating the same pathway as exercise is not the same as producing exercise-like results in people, and for AICAR the human efficacy data simply does not exist. This article walks through each documented benefit, leads with the evidence behind it, and flags every time a result comes from animals rather than humans — because for AICAR, nearly all of it does.
Research-context information only. AICAR is an investigational drug not approved by the FDA. Protocols, doses, and reactions reported below come from published clinical trials and self-reported community sources. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.
How AICAR Works
AICAR is an AMP mimetic. Once inside a cell it is phosphorylated to ZMP, which occupies the same regulatory site as AMP and allosterically activates AMPK without actually changing the cell's AMP-to-ATP ratio. AMPK is the enzyme that senses low cellular energy and shifts metabolism toward fuel production — the same switch endurance exercise pulls.
From that single lever, the published mechanism branches in three directions, each documented in animal or cell studies rather than human ones:
Glucose uptake via GLUT4 translocation, independent of insulin
Fatty-acid oxidation via inhibition of acetyl-CoA carboxylase, which lowers malonyl-CoA and de-represses fat-burning
Mitochondrial biogenesis via direct phosphorylation of PGC-1alpha
Every step below is real molecular biology. What is not established is that pulling this lever with injected AICAR produces meaningful fat loss, endurance, or performance changes in humans. For dose figures documented in the research and in community sources, see the AICAR dosing guide.
AMPK-Driven Endurance Reprogramming (Mouse Data)
The benefit AICAR is sold on comes from one paper. A 2008 Cell study by Narkar and colleagues reported that sedentary mice dosed with AICAR for roughly four weeks ran about 44% farther than vehicle-treated mice. The authors attributed the effect to AMPK activating PPARdelta, which reprogrammed muscle toward oxidative, fatigue-resistant fibers — the profile endurance training builds. The paper's "exercise mimetic" framing is where the "exercise in a pill" idea originated.
Two honesty flags belong on this result every time it is cited. First, Narkar's roughly 44%-farther finding is in mice, not people. Second, the dose used — around 500 mg/kg/day by subcutaneous injection in Narkar's mouse protocol — does not translate to humans by simple milligram-per-kilogram scaling; naive scaling of rodent doses is invalid. No controlled human trial has reproduced an endurance benefit from AICAR.
50mg · sold research-use-only · we may earn a commission
Fat and Glucose Oxidation (Rat Data)
The metabolic case for AICAR rests on rodent muscle experiments. A 2005 Journal of Physiology study by Smith and colleagues reported that AICAR simultaneously raised both fatty-acid oxidation and glucose oxidation in resting rat soleus muscle, via AMPK. Mechanistically, AMPK phosphorylates acetyl-CoA carboxylase, which lowers malonyl-CoA and releases the brake on CPT-1 so more fat enters the mitochondria to be burned; in parallel, AMPK drives GLUT4 to the cell surface for insulin-independent glucose uptake.
This is the mechanistic basis for the "fat loss" and "glucose disposal" claims attached to AICAR. But Smith's 2005 findings describe isolated rat muscle, not body-composition change in humans. There is no controlled human trial reporting that AICAR reduces body fat or improves glucose control in people. Community sources sometimes describe modest fat loss over four to eight weeks, often stacking AICAR with GW-501516 (cardarine) in a pattern traced back to the mouse Narkar protocol; those are unverified anecdotes from unregulated settings, not trial outcomes, and no human study corroborates them.
Mitochondrial Biogenesis via PGC-1alpha
The link between AMPK and building new mitochondria is well established at the molecular level. A 2007 PNAS study by Jager and colleagues reported that AMPK directly phosphorylates PGC-1alpha — the master regulator of mitochondrial biogenesis — in skeletal muscle, which helps explain how AMPK activation shifts muscle toward a more oxidative, endurance-type phenotype.
Because AICAR activates AMPK directly, this PGC-1alpha pathway is the plausible mechanistic route from an AICAR dose to more mitochondria. Jager's 2007 work characterizes the signaling step itself, in muscle-cell and mouse systems; it is a mechanism paper, not evidence that injected AICAR increases mitochondrial density or performance in humans.
What the Human Data Actually Shows
The only rigorous human trials of this molecule tested acadesine — the same compound — as a cardioprotective agent during heart surgery, not as a fitness aid. Early signals looked promising: a 1997 JAMA meta-analysis by Mangano pooled five randomized trials in roughly 4,000 CABG patients and reported an early signal of reduced perioperative heart attack and cardiac death.
That signal did not hold up. The definitive Phase 3 trial, RED-CABG, reported by Newman and colleagues in JAMA in 2012, enrolled roughly 3,000 patients and found no benefit — event rates were essentially identical between acadesine and placebo (about 5.1% versus 5.0%) — and the trial was stopped for futility. This negative result is why acadesine was never approved for any indication. It is the single most rigorous human test of the molecule, and it failed its endpoint. On the safety side, the acadesine trials documented asymptomatic increases in uric acid (AICAR is metabolized to uric acid), transient rises in creatinine, and infusion-related low blood pressure; long-term safety of chronic AICAR in healthy people has never been studied.
How AICAR Relates to MOTS-c
A useful way to frame AICAR is alongside MOTS-c, a compound that reaches the same destination by a different road. A 2015 Cell Metabolism study by Lee and colleagues reported that MOTS-c activates AMPK indirectly — it interferes with the folate cycle, which causes endogenous AICAR and ZMP to accumulate inside the cell, and that buildup activates AMPK. In other words, MOTS-c works partly by generating the body's own AICAR-like signal, while injected AICAR supplies a synthetic AMP look-alike directly.
The two share the same downstream outputs — GLUT4, fatty-acid oxidation, PGC-1alpha, oxidative muscle programming — and they share the same evidence gap. Neither has controlled human data establishing physique or performance benefits, and both are prohibited in sport by WADA at all times. For a fuller breakdown of the peptide side of that pathway, see the MOTS-c benefits article.
Bac Water Made for Peptides
Don't risk a $300 peptide on generic bac water.
Most cloudy reconstitutions trace back to one thing — and it isn't the peptide. Sterile, non-pyrogenic, 0.9% benzyl alcohol — formulated for peptide reconstitution, not repackaged from generic stock.
✓ 0.9% benzyl alcohol✓ Made for peptides✓ 30 mL multi-dose
30ml from $18.75 · Ships fast · Code thepeptidecatalog
Frequently Asked Questions
What did research report about AICAR and endurance?
The most-cited finding comes from a 2008 Cell study by Narkar and colleagues, which reported that sedentary mice given AICAR for about four weeks ran roughly 44% farther than vehicle-treated mice, an effect the authors attributed to AMPK and PPARdelta reprogramming of muscle fibers. This result is in mice. No controlled human trial has reproduced an endurance benefit from AICAR.
What does human evidence show for AICAR and fitness or fat loss?
There is no controlled human trial showing AICAR improves body composition, endurance, or athletic performance. The only rigorous human data comes from cardiac-surgery trials of acadesine (the same molecule): the definitive Phase 3 RED-CABG trial reported by Newman and colleagues in 2012 found no benefit and was stopped for futility, which is why acadesine was never approved. The endurance and fat-loss claims trace to animal studies, not human ones.
How does AICAR compare to MOTS-c mechanistically?
Both converge on the same AMPK switch. AICAR flips it directly — it is phosphorylated to ZMP, which mimics AMP and activates AMPK. MOTS-c does it indirectly: a 2015 Cell Metabolism study by Lee and colleagues reported that MOTS-c inhibits the folate cycle, causing endogenous AICAR/ZMP to accumulate, which then activates AMPK. Neither compound has established human performance or physique data.
What is AICAR's status in regulated sport?
The World Anti-Doping Agency prohibits AICAR under class S4 (hormone and metabolic modulators), in the AMPK-activator subsection, and it is banned at all times — both in and out of competition, not only on competition day. USADA names AICAR explicitly. It is sold only as a research chemical labeled not for human consumption and has never been FDA-approved.
Narkar VA, Downes M, Yu RT, et al. AMPK and PPARdelta agonists are exercise mimetics. Cell. 2008;134(3):405-415. PubMed
Smith AC, Bruce CR, Dyck DJ. AMP kinase activation with AICAR simultaneously increases fatty acid and glucose oxidation in resting rat soleus muscle. J Physiol. 2005;565(Pt 2):537-546. PubMed
Jager S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci U S A. 2007;104(29):12017-12022. PubMed
Mangano DT. Effects of acadesine on myocardial infarction, stroke, and death following surgery: a meta-analysis of the 5 international randomized trials. JAMA. 1997;277(4):325-332. PubMed
Newman MF, Ferguson TB, White JA, et al. Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial. JAMA. 2012;308(2):157-164. PubMed
Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PubMed
